Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose–response meta-analyses

医学 哮喘 不利影响 吸入性皮质类固醇 肺病 内科学 重症监护医学 慢性阻塞性肺病 呼吸道疾病 支气管扩张剂 皮质类固醇 梅德林 吸入
作者
Xiaofeng Pu,Yinhui Zhang,Li Peng,Yunbei Huang,Xinrui Jiang,Maolin Wang,Zhengji Zhang,Mengyao Xu,Guojun Wang
出处
期刊:Evidence-based Medicine [BMJ]
卷期号:31 (1): 23-35 被引量:4
标识
DOI:10.1136/bmjebm-2024-113216
摘要

OBJECTIVES: This study aimed to evaluate the associations between inhaled corticosteroids (ICSs) and adverse events (AEs) in adults with asthma or chronic obstructive pulmonary disease (COPD) and to explore variations by ICS type and dosage. DESIGN AND SETTING: Medline/PubMed, Embase, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were searched from inception to 20 February 2025. Data extraction and synthesis were performed, estimating risk ratios (RRs) with 95% confidence intervals (CI) or credible intervals (CrI) through pairwise and network meta-analysis (NMA), and an NMA using the Emax model was employed to find the dose-response relationships of the AEs of each ICS. Risk of bias was evaluated across both pairwise and NMAs. The certainty of evidence, based on the GRADE approach, was assessed exclusively for the NMA estimates. PARTICIPANTS: Adults diagnosed with asthma or COPD treated with ICSs compared with non-ICS controls or those receiving different types or doses of ICSs. MAIN OUTCOME MEASURES: The primary outcomes were AEs, including pneumonia, oral candidiasis, upper respiratory tract infection (URTI), fracture, diabetes, cataract and plasma cortisol abnormalities. Secondary outcomes included efficacy-related endpoints: asthma exacerbations, COPD exacerbations and all-cause mortality. RESULTS: 129 trials (120 900 participants) were included. According to pairwise meta-analysis, ICSs were associated with a higher risk of pneumonia (RR 1.49, 95% CI 1.38 to 1.61) and oral candidiasis (RR 2.29, 95% CI 2.01 to 2.60) and with a slightly higher risk of URTI (RR 1.17, 95% CI 1.10 to 1.25), compared with control. Besides, ICSs were linked to a reduced risk of asthma exacerbations (RR 0.30, 95% CI 0.20 to 0.45) and COPD exacerbations (RR 0.90, 95% CI 0.86 to 0.94) vs control. The results of the NMA that explored differences by ICS type showed that beclomethasone and fluticasone increased pneumonia risk compared with control, with absolute risk increases of up to 2.3%. Fluticasone also showed a slightly higher pneumonia risk than budesonide. Besides, mometasone, beclomethasone, budesonide and fluticasone were associated with increased risk of oral candidiasis, with the highest increase observed for mometasone (4.3%). In contrast, ciclesonide consistently showed lower risk across comparisons, reducing oral candidiasis by up to 4.5% with other ICSs. Fluticasone modestly increased URTI, while ciclesonide reduced it. Budesonide and mometasone were also associated with a small increase in cataract risk. Most of the outcomes reported here were supported by moderate- to high-certainty evidence. Furthermore, the dose-response relationship estimated from the Emax model indicated significant associations between fluticasone dose and the risks of pneumonia and URTI, between multiple ICS doses and oral candidiasis and between budesonide dose and cataract. CONCLUSIONS: ICSs are correlated with the escalated risk of pneumonia, oral candidiasis and URTI in adult patients with asthma or COPD, but ICSs could reduce asthma exacerbations and COPD exacerbations. Fluticasone, beclomethasone, budesonide and mometasone are independently linked to certain AEs, and some Emax dose-response relationships are detected.Our findings may help guide individualised ICS use by informing benefit-risk considerations across various formulations and dosing regimens. PROSPERO REGISTRATION NUMBER: CRD42024527797.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
鹿吖鹿发布了新的文献求助10
刚刚
1秒前
cxhm完成签到,获得积分10
1秒前
李博宇完成签到,获得积分10
1秒前
李国涛发布了新的文献求助10
1秒前
风趣的胜完成签到,获得积分10
1秒前
慕青的应助被无雨采纳,获得10
2秒前
2秒前
2秒前
znn发布了新的文献求助10
2秒前
2秒前
zhang关注了科研通微信公众号
2秒前
Vivi发布了新的文献求助10
3秒前
3秒前
3秒前
吴一斤完成签到,获得积分10
4秒前
小二郎的应助被江江采纳,获得20
4秒前
桐桐的应助被烹全鱼宴采纳,获得10
4秒前
心房的锁完成签到,获得积分10
4秒前
4秒前
ABCD完成签到 ,获得积分10
4秒前
Wendy完成签到,获得积分10
5秒前
5秒前
Orange的应助被www采纳,获得10
5秒前
6秒前
斯文败类的应助被风笛采纳,获得10
6秒前
6秒前
6秒前
dd发布了新的文献求助10
6秒前
6秒前
ZM发布了新的文献求助10
6秒前
6秒前
双儿完成签到,获得积分10
7秒前
luiii发布了新的文献求助30
7秒前
jianglai发布了新的文献求助10
8秒前
8秒前
一生所爱发布了新的文献求助10
8秒前
辰辰发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519